Trim2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
| symbol = TRIM2
| name = Tripartite Motif Containing 2
| geneID = 23321
| chromosome = 4
| location = 4q31.3
| OMIM = 614434
| Ensembl = ENSG00000109654
| EntrezGene = 23321
| UniProt = Q9C0B1
}}
The TRIM2 gene encodes Tripartite Motif Containing 2 (TRIM2), an E3 ubiquitin ligase protein that plays critical roles in protein quality control, neuronal function, and cellular defense mechanisms. TRIM2 is a member of the TRIM (Tripartite Motif) family of proteins characterized by their RING finger, B-box, and coiled-coil domains. Mutations in TRIM2 have been linked to hereditary spastic paraplegia and Charcot-Marie-Tooth disease, highlighting its importance in motor neuron function. TRIM2 is a neuron-specific E3 ligase that regulates the ubiquitination of key proteins involved in cytoskeletal dynamics, axonal transport, and synaptic function.
¶ Gene Structure and Protein
The TRIM2 gene spans approximately 30 kb on chromosome 4q31.3 and consists of 6 exons. The gene encodes a 741-amino acid protein with the characteristic TRIM domain architecture.
The TRIM2 protein (741 amino acids, ~85 kDa) contains multiple functional domains:
- RING Finger Domain: Coordinates zinc ions and mediates E2 ubiquitin-conjugating enzyme binding
- B-Box Type 1 Domain: Zinc-binding domain involved in protein-protein interactions
- Coiled-Coil Region: Mediates dimerization and substrate recognition
- C-terminal Region: Contains the substrate-binding and ubiquitination activity
TRIM2 serves as a neuron-specific E3 ubiquitin ligase:
- Protein Quality Control: Targets misfolded and damaged proteins for proteasomal clearance
- Proteasomal Degradation: Catalyzes polyubiquitination for 26S proteasome targeting
- Autophagic Degradation: Mediates selective autophagy through ubiquitin tagging
- Signal Regulation: Controls signaling pathway components through ubiquitination
TRIM2 participates in multiple cellular processes:
- Cytoskeletal Regulation: Interacts with the microtubule cytoskeleton and regulates actin dynamics
- Neuronal Development: Critical for proper axonal outgrowth, guidance, and branching
- Axonal Transport: Regulates microtubule-based motor protein function
- Synaptic Function: Modulates synaptic protein turnover and plasticity
- Innate Immunity: Involved in antiviral defense mechanisms
- Autophagy Regulation: Links ubiquitination to autophagic degradation
TRIM2 shows tissue-specific expression with highest levels in neuronal tissue:
- Central Nervous System: High expression in motor neurons, cortical neurons, hippocampal pyramidal cells, and cerebellar Purkinje cells
- Peripheral Nervous System: Schwann cells and peripheral neurons
- Muscle: Low expression in skeletal muscle tissue
- Heart: Minimal cardiac expression
TRIM2 mutations cause autosomal recessive hereditary spastic paraplegia (SPG79):
- Motor Neuron Degeneration: Upper motor neuron involvement leads to spasticity
- Axonal Pathology: Defects in axonal transport and cytoskeletal integrity
- Ubiquitin-Proteasome System Dysfunction: Impaired protein clearance in neurons
- Onset: Typically in childhood or adolescence
- Progression: Progressive spasticity and weakness
TRIM2 is associated with CMT neuropathy:
- Peripheral Neuropathy: Demyelinating and axonal features
- Motor and Sensory Deficits: Distal muscle weakness, atrophy, and sensory loss
- Nerve Conduction Abnormalities: Reduced nerve conduction velocities
- Foot Deformities: Characteristic pes cavus and hammertoes
TRIM2 dysfunction contributes to ALS pathogenesis:
- Protein Aggregation: TRIM2 may be sequestered into ALS inclusions containing TDP-43
- Motor Neuron Vulnerability: Links to selective motor neuron degeneration
- Ubiquitin System Impairment: Common pathway in ALS pathogenesis[1]
- Axonal Transport Defects: TRIM2 regulates proteins critical for axonal transport
- Protein Quality Control: TRIM2 dysfunction may contribute to Aβ accumulation
- Tau Ubiquitination: TRIM2 may regulate tau degradation
- Synaptic Dysfunction: Altered TRIM2 expression affects synaptic protein turnover
- Alpha-Synuclein Clearance: TRIM2 may play a role in清除α-syn aggregates
- Ubiquitin-Proteasome System: PD-related dysfunction in UPS
TRIM2 catalyzes ubiquitination through a cascade:
- E1 Activation: Ubiquitin-activating enzyme activates ubiquitin
- E2 Conjugation: Ubiquitin-conjugating enzyme receives ubiquitin
- E3 Ligation: TRIM2 transfers ubiquitin to target proteins
TRIM2 typically generates Lys48-linked polyubiquitin chains for proteasomal degradation.
| Substrate |
Function |
Disease Relevance |
| NF-κB essential modulator |
Signaling |
Inflammation |
| Myosin IIA |
Cytoskeleton |
ALS |
| ALS-associated proteins |
Aggregation |
ALS |
- NF-κB Pathway: TRIM2 regulates NF-κB signaling through ubiquitination
- p53 Pathway: TRIM2 can modulate p53 activity
- mTOR Pathway: Links nutrient signaling to protein quality control
| Strategy |
Target |
Stage |
| Gene Therapy |
TRIM2 expression |
Preclinical |
| UPS Modulators |
TRIM2 activity |
Research |
| Neuroprotective |
TRIM2 substrates |
Research |
- Blood-Brain Barrier: CNS delivery challenges
- Specificity: Achieving selective modulation
- Timing: Optimal intervention point in disease progression
- TRIM2-/- mice: Show motor coordination deficits and axonal abnormalities
- Motor neuron-specific KO: Phenocopy features of HSP and CMT
- HSP mouse models: TRIM2 mutations produce spastic phenotype
- CMT models: TRIM2 deficiency causes peripheral neuropathy
- Gene Therapy: AAV-mediated TRIM2 delivery
- Biomarkers: TRIM2 activity as biomarker for protein quality control
- Substrate Identification: Mapping TRIM2 ubiquitination targets
- Small Molecule Modulators: Developing TRIM2-targeted compounds
The study of Trim2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Yamoah A, et al. (2018). "TRIM2 mutations cause hereditary spastic paraplegia." Am J Hum Genet 103(2): 293-302. PMID:30057032
- Balastik M, et al. (2020). "TRIM2 in Charcot-Marie-Tooth disease." Neurology 95(8): 1123-1134. PMID:32855380
- Chen L, et al. (2021). "TRIM proteins in neurodegeneration." Nat Rev Neurosci 22(8): 485-500. PMID:34224635
- Song P, et al. (2022). "E3 ubiquitin ligases in ALS and related disorders." Brain 145(5): 1687-1702. PMID:35674891
- Nakamura N, et al. (2023). "TRIM2 and protein quality control in neurons." Cell Rep 42(3): 112156. PMID:36933218